Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics


Axsome Therapeutics, Inc. (AXSM): $37.96

0.93 (+2.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AXSM Stock Price Chart Interactive Chart >

Price chart for AXSM

AXSM Price/Volume Stats

Current price $37.96 52-week high $71.50
Prev. close $37.03 52-week low $19.38
Day low $34.68 Volume 5,500,700
Day high $39.73 Avg. volume 1,125,397
50-day MA $29.27 Dividend yield N/A
200-day MA $32.97 Market Cap 1.48B

Axsome Therapeutics, Inc. (AXSM) Company Bio


Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.


AXSM Latest News Stream


Event/Time News Detail
Loading, please wait...

AXSM Latest Social Stream


Loading social stream, please wait...

View Full AXSM Social Stream

Latest AXSM News From Around the Web

Below are the latest news stories about Axsome Therapeutics Inc that investors may wish to consider to help them evaluate AXSM as an investment opportunity.

Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review

The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.

Yahoo | February 18, 2022

Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time

GlobeNewswire | February 15, 2022

Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:40 PM Eastern Time.

GlobeNewswire | February 11, 2022

My Top High-Conviction Home Run Stock

Although home run stocks, or equities capable of producing life-altering returns in a short period of time, are far from commonplace, the biopharmaceutical industry has been fertile ground for explosive growth vehicles for a number of years now. While developing pharmaceuticals is fraught with risk at nearly every step, several clinical-stage biotechs have, in fact, overcome these long odds over the past 10 years to bring important new medicines to market. Investors, in turn, ought not overlook the extraordinary risks associated with potential home run plays in the complex world of biopharmaceuticals.

Yahoo | February 10, 2022

Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

Yahoo | February 9, 2022

Read More 'AXSM' Stories Here

AXSM Price Returns

1-mo N/A
3-mo -8.29%
6-mo 0.48%
1-year -45.51%
3-year 47.42%
5-year 590.18%
YTD 0.48%
2021 -53.63%
2020 -21.18%
2019 3,565.25%
2018 -49.64%
2017 -17.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7259 seconds.